ATE169826T1 - Iontophoretische verbesserte verabreichung von medikamenten - Google Patents

Iontophoretische verbesserte verabreichung von medikamenten

Info

Publication number
ATE169826T1
ATE169826T1 AT93300198T AT93300198T ATE169826T1 AT E169826 T1 ATE169826 T1 AT E169826T1 AT 93300198 T AT93300198 T AT 93300198T AT 93300198 T AT93300198 T AT 93300198T AT E169826 T1 ATE169826 T1 AT E169826T1
Authority
AT
Austria
Prior art keywords
morpholine
alkyl
lipid modifier
water
iontophoresis
Prior art date
Application number
AT93300198T
Other languages
English (en)
Inventor
Carlos M Samour
Solomon R Eisenberg
Original Assignee
Macrochem Corp
Univ Boston
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Macrochem Corp, Univ Boston filed Critical Macrochem Corp
Application granted granted Critical
Publication of ATE169826T1 publication Critical patent/ATE169826T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/0208—Tissues; Wipes; Patches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/4906—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom
    • A61K8/4913—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom having five membered rings, e.g. pyrrolidone carboxylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/4973—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
    • A61K8/498—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom having 6-membered rings or their condensed derivatives, e.g. coumarin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0009—Galenical forms characterised by the drug release technique; Application systems commanded by energy involving or responsive to electricity, magnetism or acoustic waves; Galenical aspects of sonophoresis, iontophoresis, electroporation or electroosmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
    • A61K2800/83—Electrophoresis; Electrodes; Electrolytic phenomena

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Birds (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Electrotherapy Devices (AREA)
AT93300198T 1992-01-21 1993-01-13 Iontophoretische verbesserte verabreichung von medikamenten ATE169826T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US82338092A 1992-01-21 1992-01-21

Publications (1)

Publication Number Publication Date
ATE169826T1 true ATE169826T1 (de) 1998-09-15

Family

ID=25238587

Family Applications (1)

Application Number Title Priority Date Filing Date
AT93300198T ATE169826T1 (de) 1992-01-21 1993-01-13 Iontophoretische verbesserte verabreichung von medikamenten

Country Status (7)

Country Link
US (1) US5527797A (de)
EP (1) EP0552879B1 (de)
JP (1) JPH05339170A (de)
AT (1) ATE169826T1 (de)
CA (1) CA2087679C (de)
DE (1) DE69320378T2 (de)
ES (1) ES2120477T3 (de)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2153485T3 (es) * 1994-07-13 2001-03-01 Alza Corp Composicion y procedimiento que incrementa la difusion percutanea por electrotransporte de una substancia.
US5736580A (en) * 1994-11-14 1998-04-07 Alza Croporation Composition, device, and method for electrotransport agent delivery
US5861439A (en) * 1994-11-14 1999-01-19 Alza Corporation Method for enhanced electrotransport agent delivery
US5620980A (en) * 1995-02-22 1997-04-15 Macrochem Corporation Method for treating hair loss
US5990179A (en) * 1995-04-28 1999-11-23 Alza Corporation Composition and method of enhancing electrotransport agent delivery
US5985316A (en) * 1995-04-28 1999-11-16 Alza Corporation Composition and method of enhancing electrotransport agent delivery
DE69630918T2 (de) 1995-06-09 2004-10-28 Hisamitsu Pharmaceutical Co., Inc., Tosu Matrix für Iontophorese
DE19610396C2 (de) * 1996-03-16 1998-11-26 Krewel Meuselbach Gmbh Dimethylsulfoxid-haltige topische Zubereitung
CA2208336A1 (en) * 1996-06-20 1997-12-20 Hisamitsu Pharmaceuticals Co., Inc. A device structure for iontophoresis
US7914814B2 (en) * 1997-09-17 2011-03-29 Strategic Science & Technologies, Llc Topical delivery of arginine of cause beneficial effects
US7629384B2 (en) * 1997-09-17 2009-12-08 Strategic Science & Technologies, Llc Topical delivery of L-arginine to cause beneficial effects
DE69826705T2 (de) * 1997-11-12 2006-02-23 Alza Corp., Palo Alto Verfahren zur dermalen verabreichung von polypeptiden
US20050203187A1 (en) * 1998-06-01 2005-09-15 Verbiscar Anthony J. Formulations useful for the treatment of varicella zoster virus infections and methods for the use thereof
US5942545A (en) * 1998-06-15 1999-08-24 Macrochem Corporation Composition and method for treating penile erectile dysfunction
US6475514B1 (en) 1998-12-03 2002-11-05 Andrew Blitzer Athletic patch
US7137975B2 (en) * 2001-02-13 2006-11-21 Aciont, Inc. Method for increasing the battery life of an alternating current iontophoresis device using a barrier-modifying agent
RU2290216C2 (ru) * 2001-04-04 2006-12-27 Алза Корпорейшн Устройство для трансдермального электротранспортного введения, содержащее резервуар с противомикробной совместимой композицией
AU2002251541A1 (en) * 2002-04-25 2003-11-10 Centre Pharmapeptides Apparatus and assembly for administering antimicrobial agent
AU2003282683A1 (en) 2002-10-04 2004-05-04 Photokinetix Inc. Photokinetic delivery of biologically active substances using pulsed incoherent light
DE10314976A1 (de) * 2003-04-02 2004-10-14 Bayer Healthcare Ag Verbesserte Penetration von Wirkstoffen in Zellen und Organe
AU2005216192B2 (en) * 2004-02-23 2010-11-04 Strategic Science & Technologies, Llc Topical delivery of a nitric oxide donor to improve body and skin appearance
US20050220439A1 (en) * 2004-03-19 2005-10-06 Carton Owen A Interactive multimedia system and method
EP1737429B1 (de) * 2004-04-19 2013-07-17 Strategic Science & Technologies, LLC Transdermale abgabe von vorteilhaften substanzen, beeinflusst von einer umgebung mit hoher ionenstärke
US9226909B2 (en) 2004-04-19 2016-01-05 Strategic Science & Technologies, Llc Beneficial effects of increasing local blood flow
US20110028548A1 (en) * 2004-04-19 2011-02-03 Strategic Science & Technologies, Llc Beneficial effects of increasing local blood flow
US8170658B2 (en) 2007-12-05 2012-05-01 The Invention Science Fund I, Llc System for electrical modulation of neural conduction
US8180446B2 (en) * 2007-12-05 2012-05-15 The Invention Science Fund I, Llc Method and system for cyclical neural modulation based on activity state
US8233976B2 (en) 2007-12-05 2012-07-31 The Invention Science Fund I, Llc System for transdermal chemical modulation of neural activity
US8195287B2 (en) * 2007-12-05 2012-06-05 The Invention Science Fund I, Llc Method for electrical modulation of neural conduction
US8989858B2 (en) 2007-12-05 2015-03-24 The Invention Science Fund I, Llc Implant system for chemical modulation of neural activity
US8165669B2 (en) * 2007-12-05 2012-04-24 The Invention Science Fund I, Llc System for magnetic modulation of neural conduction
US8170659B2 (en) * 2007-12-05 2012-05-01 The Invention Science Fund I, Llc Method for thermal modulation of neural activity
US20090149797A1 (en) * 2007-12-05 2009-06-11 Searete Llc, A Limited Liability Corporation Of The State Of Delaware System for reversible chemical modulation of neural activity
US8165668B2 (en) * 2007-12-05 2012-04-24 The Invention Science Fund I, Llc Method for magnetic modulation of neural conduction
US20100022494A1 (en) * 2008-07-24 2010-01-28 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Method, device, and kit for maintaining physiological levels of steroid hormone in a subject
US20100022991A1 (en) * 2008-07-24 2010-01-28 Searete Llc, A Limited Liability Corporation Of The State Of Delaware System and device for maintaining physiological levels of steroid hormone in a subject
US20100022497A1 (en) * 2008-07-24 2010-01-28 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Method for treating or preventing a cardiovascular disease or condition utilizing estrogen receptor modulators based on APOE allelic profile of a mammalian subject
US11684624B2 (en) 2009-06-24 2023-06-27 Strategic Science & Technologies, Llc Treatment of erectile dysfunction and other indications
EP2445493A1 (de) 2009-06-24 2012-05-02 Strategic Science & Technologies, LLC Topische zusammensetzung mit naproxen
US12138268B2 (en) 2009-06-24 2024-11-12 Strategic Science & Technologies, Llc Treatment of erectile dysfunction and other indications
US9463158B2 (en) 2009-06-24 2016-10-11 Strategic Science & Technologies, Llc Treatment of erectile dysfunction and other indications
CN102481275B (zh) 2009-06-24 2014-07-23 战略科学技术有限公司 含有布洛芬的表面组合物
CA2785846C (en) 2009-12-31 2015-07-07 Kempharm, Inc. Amino acid conjugates of quetiapine, process for making and using the same
SI2544536T1 (sl) 2010-03-11 2019-03-29 Kempharm, Inc. Maščobno kislinski konjugati kvetiapina proces za njih izdelavo in uporabo
US9289495B2 (en) 2010-12-29 2016-03-22 Strategic Science & Technologies, Llc Systems and methods for treatment of allergies and other indications
CA3093231A1 (en) 2018-03-07 2019-09-12 Soovu Labs, Inc. Systems and methods for improved pain relief from stimulation of thermal fibers

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4861764A (en) * 1986-11-17 1989-08-29 Macro Chem. Corp. Percutaneous absorption enhancers, compositions containing same and method of use
ATE146087T1 (de) * 1989-10-23 1996-12-15 Theratech Inc Vorrichtung für iontophorese unter verwendung einer durchfluss-kontrollierenden membran
US5023085A (en) * 1989-11-29 1991-06-11 Pfizer Inc. Transdermal flux enhancers in combination with iontophoresis in topical administration of pharmaceuticals
US5167616A (en) * 1989-12-14 1992-12-01 Alza Corporation Iontophoretic delivery method
AU664178B2 (en) * 1991-03-19 1995-11-09 Vithal J. Rajadhyaksha Compositions and method comprising aminoalcohol derivatives as membrane penetration enhancers
US5131403A (en) * 1991-06-05 1992-07-21 Becton Dickinson And Company Method for obtaining blood using iontophoresis

Also Published As

Publication number Publication date
ES2120477T3 (es) 1998-11-01
EP0552879A1 (de) 1993-07-28
CA2087679A1 (en) 1993-07-22
US5527797A (en) 1996-06-18
DE69320378T2 (de) 1999-04-29
EP0552879B1 (de) 1998-08-19
CA2087679C (en) 2004-08-17
JPH05339170A (ja) 1993-12-21
DE69320378D1 (de) 1998-09-24

Similar Documents

Publication Publication Date Title
DE69320378D1 (de) Iontophoretische verbesserte Verabreichung von Medikamenten
FI914961A0 (fi) Peptidfoereningar, foerfarande foer deras framstaellning och dessa innehaollande farmaceutisk blandning.
WO2003059880A1 (en) Amino alcohol derivative or phosphonic acid derivative and medicinal composition containing these
DK0736018T3 (da) 4,5-Diaryloxazolderivater
NO913750L (no) Fremgangsmaate for fremstilling av terapeutisk aktive heterocykliske derivater.
HUT67285A (en) Cyclic ureas and analogues and pharmaceutical compositions
EP1312601A4 (de) Carbonsäurederivate, verfahren zu deren herstellung und medikamente, die diese als wirkstoff enthalten
FI891176A0 (fi) Peptidfoereningar, foerfarande foer deras framstaellning och dessa innehaollande farmaceutiska blandningar.
MX9800867A (es) Halogenobencimidazoles y su empleo como microbicidas.
ATE172731T1 (de) Pyrazolopyridinverbindung und verfahren zu ihrer herstellung
KR970701698A (ko) 프로스타글란딘 i₂작용물질로서의 나프탈렌 유도체(naphthalene derivatives as prostaglandin i₂agonists)
CA2360360A1 (en) Piperidyl benzamide compounds, composition containing same and their use thereof
KR910009712A (ko) 세펨 화합물 및 이의 제조방법
OA09119A (fr) Nouveaux céphèmes et leur préparation.
DE69229637D1 (de) Oxazolidone Derivative als Monoamine-Oxidaseinhibitoren
KR950703941A (ko) 일산화질소 합성 억제제(nitrogen monoxide synthesis inhibitor)
ATE122669T1 (de) Zearalanol-derivate mit anabolytischer wirkung.
RU94016524A (ru) Циклические уретаны, пригодные в качестве средств против аритмии и фибриляции, способ лечения, фармацевтическая композиция
EP0414903A4 (en) New thioproline derivative
ATE496879T1 (de) Harnstoff-derivate als inhibitoren von aspartylprotease
DE69024154D1 (de) Pyrimidoindolderivate und Verfahren zu ihrer Herstellung
AR010955A1 (es) Ureas n,n'-sustituidas y el empleo de las mismas como medicamento.
ATE228359T1 (de) Hemmung der leukotrienbiosynthese mittels harnstoffderivaten
RU2002126568A (ru) Средство для лечения заболевания, обусловленного стенозирующим поражением сосудов
ATE267593T1 (de) Ester enthaltende zusammensetzungen zur behandlung von parasitischem befall in organismen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties